GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Why Does Cell Identity Matter?

Cell identity matters because different cells have different biological abilities. In a proposed stem-cell treatment, knowing exactly which cells are being used helps you judge whether the research, risks, and regulatory approval apply to that preparation. A shared label such as “stem cells” does not make two treatments interchangeable.

Cell identity means what kind of cells are present. To assess a treatment, you also need their source, processing history, and test results. Identity alone does not establish that a treatment is safe or effective.

Why Does Cell Identity Matter?

What an approval actually covers

A specific example shows why the name matters. On December 18, 2024, the US FDA approved Ryoncil (remestemcel-L-rknd), an allogeneic bone marrow-derived mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. That approval concerns a named product and a defined patient group, not every preparation called “stromal cells” or “stem cells” Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

Four details to check before comparing treatments

Compare these details before treating a study as evidence for an offer. Differences do not prevent comparison, but they can limit which conclusions transfer.

  • Cell type. Embryonic stem cells are pluripotent: they can give rise to the body’s different cell types. Adult tissue stem cells generally produce a more limited range. Induced pluripotent stem cells, or iPSCs, are adult cells reprogrammed to a pluripotent state. These categories describe different biological capabilities, not a ranking of treatment quality What are stem cells.
  • Source. Ask which tissue supplied the cells and whether they come from you or a donor. Cells from your own body are autologous; cells from another person are allogeneic.
  • Processing. Ask whether the final preparation is a fresh mixture, a population expanded in culture, or a selected cell population. Culture expansion and selection are not mutually exclusive. The starting tissue alone does not identify the final contents.
  • Test results. Ask how the laboratory confirms identity and which additional quality checks it performs. Surface-marker testing, viability (the proportion of living cells), and sterility answer different questions. Passing one check does not establish that the others were passed.

For culture-expanded mesenchymal stromal cells, the 2006 ISCT position statement proposed a laboratory definition based on adherence to plastic, a specified surface-marker profile, and the ability to differentiate into bone, fat, and cartilage cell lineages under laboratory conditions. Its proposed thresholds include at least 95% expression of CD105, CD73, and CD90, and no more than 2% expression of the specified exclusion markers. These are laboratory characterization criteria, not evidence that an injection repairs tissue in a patient 16923606.

Why similar labels can hide different contents

A same-day tissue mixture, a cultured cell population, and a cell-free preparation are not interchangeable. Exosome preparations, for example, should not be described as living-cell treatments. The FDA’s consumer information distinguishes unapproved offerings involving cells, tissue-derived products, and exosomes Important patient and consumer information about regenerative medicine therapies.

Preparation What to establish Evidence mismatch to watch for
Fresh, same-day mixture Which populations are present and how they were measured A cultured-cell study cited without showing that its findings apply to this mixture
Cultured cell population Which cells were expanded and how the final batch was characterized A study using a different source, process, or final cell population
Cell-free preparation Which components it contains and how the amount is measured Living-cell treatment results presented as proof for a product containing no living cells

When a dose is expressed as a cell count, ask which cells were counted and whether the figure refers to living cells.

What identity testing can and cannot tell you

The FDA reports serious harms associated with unapproved regenerative medicine products, including blindness, tumor formation, neurological events, infections, and inflammatory or immune reactions. These reports do not establish a single risk rate for every cell type or treatment route Important patient and consumer information about regenerative medicine therapies.

Identity testing helps establish what a preparation contains; it cannot remove treatment risks. Viability and sterility results provide additional information, but they do not prove clinical benefit or guarantee safety. Ask the treating clinician to explain the risks of the exact preparation, collection procedure, and administration route, including the possibility of bleeding, pain, or infection from tissue collection.

Match the evidence and paperwork to the offer

A study’s relevance depends on more than the cell name. Check the source, processing, dose, route, disease, and patient group. Then check whether the study measured an outcome that matters to you, how long participants were followed, and what adverse events occurred. Matching cell identity is necessary for interpreting the claim, but is not sufficient to establish benefit.

Trial registration and FDA establishment registration are not proof of FDA approval or lawful marketing. A trial listing also does not, by itself, demonstrate that a treatment works Important patient and consumer information about regenerative medicine therapies.

In Japan, distinguish a product’s marketing approval from a clinic’s filed treatment plan. PMDA provides approved-product lists and review reports for regenerative medical products 0003. Separately, Article 4 of Japan’s Act on the Safety of Regenerative Medicine requires advance submission of a provision plan and prior committee opinion on compliance with provision standards. A plan filing is not the same as product marketing approval and should not be read as proof of clinical effectiveness En.

The ISSCR guidelines provide a framework for evaluating research rigor and clinical translation; they do not endorse an individual clinic’s treatment. Ask for human evidence relevant to the proposed use rather than relying on a testimonial or a laboratory certificate Guidelines.

Nine questions to take to a consultation

For a practical comparison, consider this hypothetical situation: an offer describes a fresh, fat-derived mixture, but its supporting paper describes culture-expanded cells. Highlight the source and processing description in each document and ask the clinician to explain the mismatch. This is a document-checking example, not a patient case or evidence that either preparation works.

  • What is the exact cell type and tissue source? Are the cells mine or from a donor?
  • Is this a fresh mixture, a cultured population, or a cell-free preparation? What does the final container hold?
  • Which identity, viability, sterility, and infection-screening checks apply, and can I see the relevant results?
  • How is the dose defined? If it is a cell count, which cells are counted and are they alive?
  • Which diagnosis and disease stage is this intended for, and how will it be administered?
  • Which human studies support this exact preparation and use? Who participated, what was measured, what comparison group was used, how long was follow-up, and what adverse events occurred?
  • Is this an approved product used within its approved indication, an investigational intervention in a supervised trial, or a clinic service under a filed plan? Which documents establish its status?
  • Who made and handled the cells, which committee reviewed the plan if applicable, and what does the consent form disclose?
  • What are the known risks for this preparation and route? Who manages complications, and what follow-up is included?

Request written answers, including an explicit statement where evidence or test information is unavailable. Unresolved discrepancies, borrowed evidence, or pressure to decide quickly are reasons to pause and seek an independent medical opinion. This guide supports document checking; it cannot verify a batch or determine whether treatment is appropriate for you.

Need to clarify the documents for a proposed treatment?

Ask which product details, test records, and regulatory documents are available. Medical interpretation and treatment decisions belong with a qualified clinician.

Ask about treatment documents